But untreated higher weight, diabetes, high blood pressure, high cholesterol, and sleep apnea can worsen while waiting
Safety Monitoring To ensure safe escalation, clinical protocols monitored: Liver enzymes (ALT, AST) Kidney function Cardiovascular markers (blood pressure, lipids) Blood glucose in diabetic and non-diabetic participants So far, no significant cardiovascular safety issues have been reported, though long-term Phase 3 data will be critical before final conclusions can be made
Call 999 or go to your nearest A&E immediately if you experience: Signs of a severe allergic reaction (anaphylaxis), including swelling of the face, lips, tongue, or throat, difficulty breathing, or a widespread rash with collapse Seek urgent medical advice if you experience: Severe or persistent vomiting that prevents you from keeping fluids down Signs of dehydration, including dizziness, dark urine, or significantly reduced urination Severe abdominal pain, particularly if it radiates to the back this may indicate pancreatitis, a rare but serious adverse effect associated with GLP-1 receptor agonists [11] [12] Pain in the upper right abdomen, fever, yellowing of the skin or eyes (jaundice), pale stools, or dark urine these may be signs of a gallbladder problem, such as gallstones or cholecystitis, which have been associated with this class of medicine and with rapid weight loss Symptoms of hypoglycaemia (low blood sugar), such as shakiness, sweating, confusion, or palpitations the risk is higher if you are also taking insulin or a sulfonylurea
Both Semaglutide and Liraglutide begin working in the body shortly after starting, but the visible effects take time
